Columnist Desiree Lama pens an open letter to her present-day self, who is in need of some support and encouragement while ...

A blood test might predict when multiple sclerosis patients are about to suffer a relapse in their symptoms, a new study says ...

The first person with multiple sclerosis was imaged in a clinical trial of a PET tracer to track myelin changes.

"EC approves argenx’s efgartigimod alfa for CIDP treatment" was originally created and published by Pharmaceutical Technology ...

Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...

New research by Sumeda Nandadasa, Ph.D., reveals how a key protein associated with Meckel-Gruber syndrome, nephronophthisis, ...

Panelists discuss exciting phase 3 trial data on a novel selective phosphodiesterase inhibitor that elevates intracellular ...

Argenx has a second FDA approval for FcRn inhibitor Vyvgart Hytrulo, adding new indication rare autoimmune disease CIDP. Skip to main content Friday 20 June 2025 . BlueSky linkedin youtube rss ...

The FDA has said it plans to deliver a decision in June on the use of Argenx’ Vyvgart Hytrulo in rare autoimmune disease chronic inflammatory demyelinating polyneuropathy (CIDP).

The brain isn’t the only place where MS lesions can develop — the disease can also attack the spinal cord, which can result in an increased risk of disability.